UOC
CERE

UBS O'Connor’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

UBS O'Connor’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,000,000
Closed -$81.8M – 648
2024
Q2 		$81.8M Sell
2,000,000
-1,230,529
-38% -$51.2M 2.3% 12
2024
Q1 		$137M Buy
3,230,529
+1,505,529
+87% +$63.2M 3.91% 5
2023
Q4 		$73.1M Buy
+1,725,000
New +$49.6M 2.3% 5

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

UBS O'Connor's CERE Position: Q3 2024 in Review

UBS O'Connor sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 2,000,000 shares — an estimated $81.8M sold.

UBS O'Connor first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $137M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • UBS O'Connor reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • UBS O'Connor sold 2,000,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $81.8M.
  • UBS O'Connor first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • UBS O'Connor's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $137M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on UBS O'Connor's 13F filing for Q3 2024, filed 14 Nov 2024.